Efficacy and Safety of Inhaled Molgramostim (rhGM-CSF) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
Status:
Completed
Trial end date:
2019-09-27
Target enrollment:
Participant gender:
Summary
This study evaluates inhaled molgramostim (recombinant human (rh) Granulocyte
Macrophage-Colony Stimulating Factor (GM-CSF)) in the treatment of autoimmune pulmonary
alveolar proteinosis patients. A third of the patients will receive inhaled molgramostim
daily for 24 weeks, a third will receive inhaled molgramostim intermittently (seven days on,
seven days off) for 24 weeks and a third will receive inhaled matching placebo for 24 weeks.